Stoke Therapeutics (NASDAQ:STOK) Rating Reiterated by HC Wainwright

Stoke Therapeutics (NASDAQ:STOK)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a report released on Wednesday, Benzinga reports. They presently have a $35.00 target price on the stock. HC Wainwright’s price target would indicate a potential upside of 119.85% from the company’s previous close.

Several other brokerages also recently weighed in on STOK. Wedbush reissued an “outperform” rating and issued a $17.00 target price on shares of Stoke Therapeutics in a research note on Thursday, July 11th. Needham & Company LLC reissued a “buy” rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a research report on Thursday, August 8th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $21.40.

Stoke Therapeutics Price Performance

Shares of NASDAQ STOK opened at $15.92 on Wednesday. The firm’s 50-day moving average is $14.29 and its two-hundred day moving average is $12.81. The company has a market capitalization of $838.19 million, a PE ratio of -6.61 and a beta of 0.96. Stoke Therapeutics has a 12-month low of $3.35 and a 12-month high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last posted its earnings results on Wednesday, August 7th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.11. The firm had revenue of $4.83 million for the quarter, compared to analyst estimates of $3.33 million. Stoke Therapeutics had a negative return on equity of 57.89% and a negative net margin of 683.35%. On average, analysts forecast that Stoke Therapeutics will post -2.18 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Barry Ticho sold 10,000 shares of the company’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $13.75, for a total transaction of $137,500.00. Following the completion of the sale, the insider now directly owns 2,485 shares in the company, valued at approximately $34,168.75. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 11.30% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Quest Partners LLC purchased a new stake in shares of Stoke Therapeutics in the second quarter worth about $29,000. Nisa Investment Advisors LLC boosted its holdings in Stoke Therapeutics by 53.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company’s stock worth $40,000 after acquiring an additional 1,038 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Stoke Therapeutics in the second quarter valued at approximately $123,000. State Board of Administration of Florida Retirement System purchased a new stake in shares of Stoke Therapeutics during the first quarter valued at approximately $141,000. Finally, The Manufacturers Life Insurance Company raised its stake in shares of Stoke Therapeutics by 16.7% during the second quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock valued at $189,000 after purchasing an additional 1,994 shares during the period.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.